dailyai.report

Engineered proteins for biologic medicines often fail during expensive, multi-year development cycles. New AI tools now predict protein structures and interactions to reduce these failure rates. MIT researchers are leveraging these models to bypass traditional trial-and-error methods. This shift allows scientists to identify viable drug candidates faster, slashing early-stage R&D costs for biotech firms.